ArticleJournal of immunology (Baltimore, Md. : 1950)2008
Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 114 citations in OpenAlex.
- Autophagy functions in lung macrophages and dendritic cells to regulate allergen-dependent inflammatory responses.Autophagy · 2026Article
- Early-life viral infections and asthma: new cells and ideas.Current opinion in pediatrics · 2025Review
- Permissive immunosuppression facilitates the expansion of ex vivo administered regulatory T cells in the lung allograft.Scientific reports · 2025Article
- Current perspectives in the epidemiology and control of lymphatic filariasis.Clinical microbiology reviews · 2025Review
- Cytokine Couture: Designer IL2 Molecules for the Treatment of Disease.ImmunoTargets and therapy · 2025Review
- Tissue-specific roles of regulatory T cells: mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications.Frontiers in immunology · 2025Review
- Interleukin 31 receptor α promotes smooth muscle cell contraction and airway hyperresponsiveness in asthma.Nature communications · 2023Article
- IL-2-based approaches to Treg enhancement.Clinical and experimental immunology · 2023Review
- Engineering IL-2 for immunotherapy of autoimmunity and cancer.Nature reviews. Immunology · 2022Review
- Regulatory T Cells, a Viable Target Against Airway Allergic Inflammatory Responses in Asthma.Frontiers in immunology · 2022Review
- IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-γ production by CD25eLife · 2021Article
- Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?European journal of immunology · 2021Review
- In Vivo Expansion of Antigen-Specific Regulatory T Cells through Staggered Fc.IL-2 Mutein Dosing and Antigen-Specific Immunotherapy.ImmunoHorizons · 2021Article
- Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms.Journal of inflammation research · 2021Review
- Bifidobacterium infantis Relieves Allergic Asthma in Mice by Regulating Th1/Th2.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Article
- IL-2-Agonist-Induced IFN-γ Exacerbates Systemic Anaphylaxis in Food Allergen-Sensitized Mice.Frontiers in immunology · 2020Article
- Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases.Journal of immunology (Baltimore, Md. : 1950) · 2019Review
- Recombinant human thrombopoietin combined with interleukin-2 improves the effects of chemosensitivity and thrombocytopenia on a basic gemcitabine and carboplatin combination therapy for non-small cell lung cancer in a nude mouse model.Journal of thoracic disease · 2019Article
- Heat shock protein 70 is a positive regulator of airway inflammation and goblet cell hyperplasia in a mouse model of allergic airway inflammation.The Journal of biological chemistry · 2019Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Regulatory T cells (Treg) play a decisive role in many diseases including asthma and allergen-induced lung inflammation. However, little progress has been made developing new therapeutic strategies for pulmonary disorders. In the current study we demonstrate that cytokine:antibody complexes of IL-2 and anti-IL-2 mAb reduce the severity of allergen-induced inflammation in the lung by expanding Tregs in vivo. Unlike rIL-2 or anti-IL-2 mAb treatment alone, IL-2:anti-IL-2 complexes dampened airway inflammation and eosinophilia while suppressing IL-5 and eotaxin-1 production. Mucus production, airway hyperresponsiveness to methacholine, and parenchymal tissue inflammation were also dramatically reduced following IL-2:anti-IL-2 treatment. The suppression in allergic airway disease was associated with a marked expansion of Tregs (IL-10(+)CD4(+)CD25(+) and Foxp3(+)CD4(+)CD25(+)) in the tissues, with a corresponding decrease in effector T cell responses. The ability of IL-2:anti-IL-2 complexes to suppress airway inflammation was dependent on Treg-derived IL-10, as IL-10(+/+), but not IL-10(-/-) Tregs, were capable of mediating the suppression. Furthermore, a therapeutic protocol using a model of established airway allergy highlighted the ability of IL-2:anti-IL-2 complexes to expand Tregs and prevent successive airway inflammation and airway hyperresponsiveness. This study suggests that endogenous Treg therapy may be a useful tool to combat the rising incidence of allergic airway disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.